Results 21 to 30 of about 6,213 (108)

Toxicity of Cytarabine Intravenous Constant Rate Infusion in Cats With Lymphoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single‐agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route,
Rachel Hanford, Katherine A. Skorupski, Robert B. Rebhun, Rachel V. Brady, Sami Al‐Nadaf, Amandine T. Lejeune   +5 more
wiley   +1 more source

Quizartinib in Combination With FLAG‐IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG‐QUIDA): A PETHEMA Phase I‐II Trial

American Journal of Hematology, Volume 101, Issue 9, Page 2258-2268, September 2026.
ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal, Javier Zambrano Márquez, Rebeca Rodríguez‐Veiga, Eduardo Rodríguez‐Arbolí, Juan Manuel Bergua‐Burgués, Susana Vives, Montserrat Arnán, Pilar Martínez Sánchez, Pilar Herrera‐Puente, Josefina Serrano‐López, Vicente Rubio, Inmaculada Marchante‐Cepillo, Marta Cervera‐Calvo, Andrés Novo García, Rosa Fernández Martín, Cristina Gil Cortés, Carlos Rodríguez‐Medina, Victor Noriega‐Concepción, Ana Alfonso‐Piérola, Carmen Loredo, María Antuña‐Casal, Blanca Boluda, Isabel Cano‐Ferri, Evelyn Acuña‐Cruz, Laura Torres‐Miñana, Joaquín Sánchez‐García, Cristina Bilbao, Maria Teresa Gómez‐Casares, David Martínez Cuadrón, Pau Montesinos   +29 more
wiley   +1 more source

Surviving Fibroblasts After Treatment With Mitomycin C Exhibit SASP‐Like Phenotype After Glaucoma Filtration Surgery

Aging Cell, Volume 25, Issue 9, September 2026.
Transcriptomic analysis using a rabbit glaucoma filtration surgery model, combined with in vitro experiments on human conjunctival fibroblasts, demonstrates that mitomycin C induces a senescence‐associated secretory phenotype (SASP)‐like state. These SASP‐like fibroblasts were selectively eliminated by the specific senolytic agent, highlighting their ...
Akitoshi Kimura, Tomokazu Fujimoto, Satoshi Iraha, Kei‐Ichiro Yasunaga, Miyuki Inoue‐Mochita, Naofumi Funagura, Shunsuke Tanigawa, Daisuke Kurotaki, Tomoaki Koga, Fumika Watanabe‐Kitamura, Utako Tsutsumi‐Kuroda, Mitsuyoshi Nakao, Toshihiro Inoue   +12 more
wiley   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 625-634, September 2026.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, Volume 32, Issue 30, 13 August 2026.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

Apigenin, Selenium, and Combinations Are Effective in Preventing 5‐Fluorouracil Induced Cardiovascular Damage

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
5‐Fluorouracil (5‐FU) induces cardiovascular toxicity by increasing ROS, MDA, Bax, and caspase‐3 while decreasing antioxidant defenses and Bcl‐2 levels. Apigenin and selenium enhance antioxidant capacity, restore Bcl‐2 expression, suppress apoptosis, and rebalance redox status.
Gözde Atila Uslu, Hamit Uslu, Taha Abdulkadir Çoban, Emine Toraman, Mustafa Özkaraca   +4 more
wiley   +1 more source

De novo or Salvage? Nucleotide Availability as a Driver of Bacterial Adaptation and Virulence

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Bacterial pathogens survive in different host environments by switching between making nucleotides by de novo synthesis and scavenging them from the host. This flexibility supports growth and virulence making nucleotide metabolism an attractive therapeutic target.
Riya Joshi, Alastair G. McEwan, Ulrike Kappler   +2 more
wiley   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat

Journal of Cellular and Molecular Medicine, Volume 30, Issue 16, August 2026.
ABSTRACT The enhancer of zeste homologue 2 inhibitor (EZH2i) Tazemetostat (EPZ‐6438) has demonstrated antitumour efficacy in various malignancies. This study aims to evaluate its radiosensitising potential and underlying mechanisms in prostate cancer (PCa). In vitro functional assays, including wound healing, Transwell invasion, EdU proliferation, flow
Tian‐Qi Du, Yuhong Ou, Rui‐Ji Liu, Yi Feng, Yaxun Li, Gang Chen, Xingyu Wu   +6 more
wiley   +1 more source